HAVN Life Sciences Stock (OTC:HAVLF), Trade Ideas

HAVN Life Sciences Inc is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind. Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, it offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Cannabis

Penny Stocks

Psychedelics

Health Care

Exclusives

Markets

Interview

General

HAVLF

PSYCF

This article was originally published in December 2021.

Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood.

This Legal Psychoactive Mushroom Reduces Stress And Pain And Encourages Longevity, Expert Says

News

Financing

Contracts

Global

Biotech psychedelics company HAVN Life Sciences Inc. (OTC: HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean (“ABO”), previously announced on July 21, 2022. 

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

Offerings

IPOs

A key player in the biotech-meets-psychedelics space, HAVN Life Sciences Inc.

Learn About HAVN Life&#39;s New Shares Consolidation, What Changes And What Remains

HAVN LIFE SCIENCES INC by HAVN LIFE SCIENCES INC.

HAVN Life Sciences Inc

PepsiCo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>) came out with quarterly earnings of $1.61 per share, beating the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $1.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5.92%. A quarter ago, it was expected that this food and beverage company would post earnings of $1.72 per share when it actually produced earnings of $1.78, delivering a surprise of 3.49%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
PepsiCo, which belongs to the Zacks Beverages - Soft drinks industry, posted revenues of $18.25 billion for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 0.62%. This compares to year-ago revenues of $17.85 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
PepsiCo shares have added about 3.9% since the beginning of the year versus the S&amp;P 500&#39;s gain of 5.1%.
What&#39;s Next for PepsiCo?
While PepsiCo has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for PepsiCo: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.22 on $22.78 billion in revenues for the coming quarter and $8.15 on $94.64 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Beverages - Soft drinks is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Coca-Cola (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>), is yet to report results for the quarter ended March 2024. The results are expected to be released on April 30.
This world&#39;s largest beverage maker is expected to post quarterly earnings of $0.69 per share in its upcoming report, which represents a year-over-year change of +1.5%. The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level.
Coca-Cola&#39;s revenues are expected to be $10.95 billion, down 0.3% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2259777/pepsico-pep-q1-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2259777">To read this article on Zacks.com click here.</a>

Earnings

Trading Ideas

PepsiCo Q1 Earnings And Revenues Beat Estimates

WIIM

Micron shares are trading higher amid strength in chip stocks. It was also reported the company will invest $100 billion over 20 years in an Upstate New York chip hub.

<a href="https://www.wsj.com/business/deals/ibm-nears-deal-for-cloud-software-provider-cf146448?mod=latest_headlines">https://www.wsj.com/business/deals/ibm-nears-deal-for-cloud-software-provider-cf146448?mod=latest_headlines</a>
&nbsp;

Wall Street Journal Reports "Takeover Could Value HashiCorp At A Premium To Its Market Value Of $4.9 Billion"

HashiCorp shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.41%

In the first quarter of 2024, the cannabis sector faces a mixed economic landscape with a notable sequential decline in sales across several states.
<a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a>, senior analyst&nbsp;of Zuanic &amp; Associates has detailed insights into the sector&#39;s performance, particularly focusing on multi-state operators (MSOs) and their exposure across pivotal states such as Arizona, Connecticut, Florida, and others.
<h2>Q1 2024 Sector-Wide Financial Highlights</h2>
Overall, Q1 saw a downward trend in sales, except for a few states like Florida and Pennsylvania.
The most significant sales declines were observed in <a href="https://www.benzinga.com/topic/connecticut-cannabis">Connecticut</a> (-6%) and Illinois (-4%), with moderate decreases across <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a> (-3%), <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35991290/analyst-inside-look-trends-and-opportunities-in-ohios-emerging-recreational-cannabi">Ohio</a> (-2%), and both Michigan and <a href="https://www.benzinga.com/topic/maryland-cannabis">Maryland</a> experiencing a -1% change.
Pennsylvania, by contrast, reported a 3% increase, showing resilience amidst broader sector struggles. Each state showcased unique trends affecting both sales and market dynamics.
<h3>Q1 2024 State-by-State Financial Performance And Leading Companies</h3>
<ul>
<li>California: Faced a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37971495/californias-weed-sales-decline-market-ripe-for-consolidation-biggest-companies-like">6% year-on-year decline</a>, adjusting to a $5 billion market size. Notable MSOs like Cresco Labs (OTC: <a class="ticker" href="https://www.benzinga.com/stock/crlbf#OTC">CRLBF</a>) and Green Thumb Industries (OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) have scaled back operations, reflecting a <a href="https://www.benzinga.com/topic/california-cannabis">strategic pivot within the state</a>. Other prominent MSOs include TerrAscend (OTC: <a class="ticker" href="https://www.benzinga.com/stock/trssf#OTC">TRSSF</a>) and 4Front Ventures (OTC: <a class="ticker" href="https://www.benzinga.com/stock/ffntf#OTC">FFNTF</a>).</li>
<li>Michigan: A standout in the sector with a robust 24% year-on-year growth, leading to $793 million in sales for the quarter. Despite stable retail prices, the wholesale market has presented challenges with narrower retailer spreads. <a href="https://www.benzinga.com/topic/michigan-cannabis">Leading MSOs in Michigan</a> include Ascend Wellness (OTC: <a class="ticker" href="https://www.benzinga.com/stock/aawh#OTC">AAWH</a>), Cresco Labs, and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37681427/marijuana-company-verano-holdings-worth-2-1b-outprices-its-expected-2024-earnings">Verano Holdings</a> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/vrnof#OTC">VRNOF</a>).</li>
<li>Illinois: While there was a sequential sales dip, the year-on-year figures were up by 6%, hinting at a market still finding its footing with <a href="https://www.benzinga.com/topic/illinois-cannabis">increased retail establishments </a>but facing pricing pressures. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38282615/cannabis-brands-leading-market-expansion-in-east-midwest-a-look-at-prices-and-trend">Dominant players</a> include Cresco Labs, Green Thumb Industries, and Curaleaf Holdings (OTC: <a class="ticker" href="https://www.benzinga.com/stock/curlf#OTC">CURLF</a>).</li>
<li>Florida: Displayed growth stability with a slight 1% sequential increase and a 14% rise compared to the previous year. The market benefits from a <a href="https://www.benzinga.com/topic/florida-cannabis">consistent expansion</a> in both retail locations and patient registration, indicating sustained demand. Leading companies are Trulieve Cannabis (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcnnf#OTC">TCNNF</a>) and Curaleaf Holdings, with significant market shares.</li>
<li>New Jersey and Nevada: Both states are grappling with market saturation and deflation, although <a href="https://www.benzinga.com/topic/nevada-cannabis">Nevada&rsquo;s</a> tourism boost offers some cushion against declining retail prices. In <a href="https://www.benzinga.com/topic/new-jersey-cannabis">New Jersey</a>, key operators include Curaleaf Holdings and Green Thumb Industries. In Nevada, the market is led by companies like Planet 13 Holdings (OTC: <a class="ticker" href="https://www.benzinga.com/stock/plnhf#OTC">PLNHF</a>) and Curaleaf Holdings, both benefiting from the tourist influx in Las Vegas.</li>
</ul>
<h3>Q1 2024 Operational Insights And MSO Performance</h3>
The rising number of retail locations, particularly in Illinois and New Jersey, has diluted revenues per store, pointing to an over-expansion that the market may not sustain in the longer term.
Leading MSOs like Ascend Wellness, Cresco Labs, and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37707380/green-thumbs-edge-over-s-p-500-etfs-cannabis-investor-confidence-propels-expansion-">Green Thumb Industries</a> have effectively managed their brand distribution, which is crucial as the market shifts towards more mainstream retail models.
<h2>Comparative Analysis: 4Q23 vs. 1Q24 Cannabis Market Trends</h2>
<h3>Sales Trends and Economic Indicators</h3>
Analyzing quarterly changes, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36745790/2024-oscars-of-marijuana-equity-analyst-nominations-spotlight-key-state-performers">the end of 2023</a> and the beginning of 2024 saw varying sales trends across key cannabis markets.
California saw a continuation of downward trends, moving from a 12% YoY decrease in 4Q23 to a 6% YoY decrease in 1Q24, suggesting a slight improvement in the market&#39;s decline rate. Conversely, Michigan exhibited strong growth in both quarters, with a 24% YoY increase in 1Q24 following a 27% YoY increase in 4Q23, highlighting its robust market expansion.
In <a href="https://www.benzinga.com/topic/arizona-cannabis">Arizona</a>, sales slightly recovered in 1Q24 with a decline of 6% YoY, compared to a 6% YoY decline in 4Q23, indicating consistent market challenges year-over-year.
<h3>Retail And Pricing Dynamics</h3>
The sector&#39;s retail landscape reflected notable differences in store economics and pricing pressures. For example, Illinois reported a sales decrease of 4% sequentially in 1Q24 after a positive trend in 4Q23 (+3% seq).
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin">Florida&#39;s market showed stable growth</a> in both quarters but with a slight increase in sales velocity from flat sequential growth in 4Q23 to +1% sequentially in 1Q24. Retail prices across these states continued to stabilize or decline slightly, impacting overall revenue per store and pointing to a trend of market saturation and increased competition.
<h3>Strategic Shifts And MSO Activities</h3>
Multi-state operators (MSOs) adjusted their operations strategically to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38226873/analyst-reacts-to-fda-commish-comments-medical-and-recreational-cannabis-could-have">accommodate changing conditions</a>, scaling their activities in saturated markets like New Jersey and Nevada while expanding in states like Florida and <a href="https://www.benzinga.com/markets/cannabis/24/02/37242307/jushi-holdings-revs-up-unleashing-torque-in-pennsylvania-and-virginias-cannabis-expansion">Pennsylvania</a>, where positive sales trends offered growth opportunities that companies like Trulieve and Curaleaf capitalized on.
Photo: AI-Generated Image.&nbsp;

Analyst Color

Equities

Large Cap

Mid Cap

Guidance

Emerging Markets

Retail Sales

Small Cap

Management

Market-Moving Exclusives

Analyst Ratings

AAWH

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FFNTF

GTBIF

PLNHF

TCNNF

TRSSF

VRNOF

Who's Winning In Weed? Analyst Looks At Cannabis Market's Big Players, Where Are The Best Bets?

Goldman Sachs&nbsp;analyst Eric Sheridan had a Neutral rating on&nbsp;Spotify Technology SA&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a price target of $277.
Spotify reported&nbsp;<a href="https://www.benzinga.com/news/earnings/24/04/38377741/music-giant-spotifys-q1-surprise-investors-cheer-premium-subscriber-growth-and-profit-bump" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2024</a>&nbsp;revenue growth of 20% year-on-year to $3.95 billion, beating the consensus of&nbsp;$3.85 billion.&nbsp;EPS of $1.05 beat the&nbsp;consensus of $0.70. 
The stock price jumped Tuesday after the print.
The analyst expects Spotify to have a positive market reaction to its first-quarter 2024 earnings report (including its forward second-quarter 2024 commentary) as the company reported roughly in-line subscriber and revenue performance across its businesses with some headwinds to forward revenue and subscriber momentum in the forward forecast.&nbsp;
In addition (and likely the more significant component of the stock reaction to this earnings report), he would focus on the positive operating momentum in both gross margins and operating margins on a mix of improved music and podcast trends with some headwind from audiobook costs operating margins benefiting from lower personnel and marketing spend.&nbsp;
In many ways, the continued momentum around the margin trajectory will likely remain supportive of the shares on the back of the potential for forward positive estimate revisions, as per the analyst.&nbsp;
Ahead of the earnings call, Sheridan expected investors to focus on SPOT management commentary on reasons for subscriber volatility (both in the reported quarter and forward commentary), any management comments about recent press reports discussing future pricing actions, additional color on forward profit margin trajectory, an update on a new permanent CFO and elements of the broader media consumption landscape.
SPOT price action: Spotify shares traded higher by 14.74% at $312.31 at the last check Tuesday.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/04/38383512/jetblue-airways-shares-witness-over-10-drop-on-disappointing-annual-outlook">JetBlue Airways Shares Witness Over 10% Drop On Disappointing Annual Outlook</a>
Photo: Esthermm on Shutterstock

Entertainment

Price Target

Reiteration

Movers

SPOT

Spotify Demonstrates Robust Financial Health With Impressive Q1 Revenue, Margin Improvements: Analyst

<a href="https://www.wsj.com/business/deals/ibm-nears-deal-for-cloud-software-provider-cf146448?mod=latest_headlines" title="https://www.wsj.com/business/deals/ibm-nears-deal-for-cloud-software-provider-cf146448?mod=latest_headlines">https://www.wsj.com/business/deals/ibm-nears-deal-for-cloud-software-provider-cf146448?mod=latest_headlines</a>

'IBM Nears Deal For Cloud-Software Provider' - Wall Street Journal

NFLX

Netflix shares are trading higher as the stock rebounds after its recent earnings report.

According to a recent CBS News poll, 39% of Americans believe the economy is "good," with 57% of respondents viewing the economy as "bad."
It's an issue President Joe Biden has to grapple with as his reelection campaign gears up, especially given that 65% of Americans remember the economy as good under former President Donald Trump, according to the poll.
In August 2022, Biden announced "zero inflation" at a time when the consumer price index (CPI) reported it was 8.5%. While he was referring to 0% month-over-month inflation at the time, it rubbed many the wrong way given the negative perception of the economy, with one Republican senator calling the claim "gaslighting."
Don't Miss:
<ul>
<li>Join the elite. Invest in Epic Games and<a href="https://www.benzinga.com/money/epic-games"> own a piece of the $17 billion Fortnite empire</a>.</li>
<li>This &#8216;Future of Gaming&#8217; startup disrupting a $272 billion industry is<a href="https://www.benzinga.com/money/gameflip-2"> now letting anyone invest for a limited time</a>.</li>
</ul>
While Biden has slightly backed off those claims in the face of still rising inflation, citing "progress" while acknowledging "prices are still too high," a report from the consulting firm McKinsey &amp; Co. uncovered what Americans are now splurging on.
It found that "<a href="https://www.benzinga.com/money/how-much-should-i-spend-on-groceries">groceries were the new biggest splurge category</a>," beating out other more discretionary categories such as eating out, travel and beauty, with millennials being the most likely to count groceries as their biggest luxury.
Trending: Invest alongside execs from Uber, Facebook and Apple in this<a href="https://www.benzinga.com/money/aura"> wellness app Transforming a $5.6 TRILLION dollar industry</a>.
While the same report cited improving consumer optimism about the economy, some commentators found humor that groceries are the biggest splurge category in the face of persistent inflation.
Former American intelligence contractor Edward Snowden posted on X, "The ratchet: first they criticize you for eating avocado toast and then for eating at all."
As many Americans struggle to keep up with the rising prices of necessities, some funds see <a href="https://www.benzinga.com/money/gameflip-2">an opportunity to profit</a>.
Alaska Permanent Fund, the largest U.S state wealth fund, recently disclosed it tripled its stake in Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) and Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), America's two largest grocery players by market share.
Even Warren Buffett's Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) is a big fan of Kroger, owning 6.9% of the grocer.
Keep Reading <a href="https://www.benzinga.com/alternative-investments/startups">About Startups</a>:
<ul>
<li>Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a></li>
</ul>

Biden's Old '0% Inflation' Comment Comes Back To Bite As McKinsey Says New Biggest Splurge For US Consumers Is Groceries

In a surprising turn of events, both proponents and opponents of cannabis reform in Hawaii joined forces to defeat a bill aimed at decriminalizing marijuana further. 
The bill, known as SB2487, would have eased penalties for possession and use of marijuana but was rejected in a vote of 16 to 9 in the state legislature. Sen. Angus McKelvey (D) explained his opposition by highlighting potential risks.
&#8220;The Senate sent a very good, reasonable, <a href="https://www.benzinga.com/markets/cannabis/24/02/37114909/hawaii-senators-approve-cannabis-legalization-bill-despite-internal-opposition-to-governors-pro-">recreational legalization</a> bill with guard rails over to the other chamber. In other states where the rush to decriminalization is outpacing their own recreational medical marijuana market; you could have a black market that could explode. Thereby undercutting and creating all the safety hazards that the bill that we sent over would have addressed,&#8221; McKelvey stated. 
The bill aimed to remove certain penalties under the <a href="https://www.benzinga.com/topic/controlled-substances-act">Uniform Controlled Substances Act</a>, specifically those related to marijuana paraphernalia. It also proposed reducing penalties for the possession and transfer without remuneration of marijuana, concentrates and infused products, while designating public smoking of marijuana as a violation under promoting a detrimental drug in the third degree. Currently, Hawaii has decriminalized possession of up to three grams of cannabis. 
The rejection of SB2487 comes after another failed legislative effort earlier this year when a recreational cannabis bill was killed in the House. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Senate Floor Session 4-22-2024 11:30am" width="500" height="281" src="https://www.youtube.com/embed/HW3agd3Pe54?start=3295&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<figcaption class="wp-element-caption">Senate Floor Session 4-22-2024 11:30am.</figcaption></figure>
<h3 class="wp-block-heading">If They Favor Cannabis, Why Would They Reject The Bill?</h3>
Cannabis regulation isn&#8217;t simply a battle between progressives and conservatives. Advocates for cannabis freedom often support decriminalization, but the complete liberalization of the cannabis market can introduce health and public safety challenges. These concerns are more effectively managed through legalization frameworks. Similarly, substances like alcohol, tobacco and prescription medications are regulated rather than merely decriminalized, just as the personal possession of nearly all plants is subject to legal oversight. 
Hawaiian decriminalization began in early 2020 after an initial attempt to pass a legalization bill failed in the House. There appears to be a consistent approach in the political discussions, which involves a trade-off between pursuing full legalization and expanding consumer rights through decriminalization measures. 
This reflects a strategic legislative effort, balancing the broader goals of legalization against more immediate, albeit limited, advancements. Meanwhile, another piece of legislation concerning cannabis is advancing. A new bill that would establish a pilot program for <a href="https://www.benzinga.com/markets/cannabis/24/04/38110997/hawaii-lawmakers-kill-cannabis-legalization-bill-but-push-decriminalization-expungement">marijuana expungements</a> is headed to the desk of Gov. <a href="https://www.benzinga.com/markets/cannabis/24/02/37022391/hawaii-discusses-cannabis-legalization-governor-says-stoners-are-less-violent-just-hungry-but-co">Josh Green </a>(D-HI). If approved, it could offer some relief and reform, compensate for the technical tie and level the scale a bit once again.

Government

Regulations

Hawaii: Cannabis Decriminalization Bill Fails Amid Unified Legislative Opposition

In the preceding three months, 10 analysts have released ratings for Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.0, a high estimate of $46.00, and a low estimate of $28.00. This upward trend is apparent, with the current average reflecting a 18.12% increase from the previous average price target of $34.71.
<img src="https://www.benzinga.com/files/images/story/2024/1713895285_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Maplebear. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Morton</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Ross Compton</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Nikhil Devnani</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Maplebear. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Maplebear compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Maplebear's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Maplebear's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Maplebear analyst ratings.</a>
<h2>Discovering Maplebear: A Closer Look</h2>
Maplebear, which does business as Instacart, is an online grocery pickup and delivery service provider currently in the United States and Canada. Instacart partners with local and national grocers who provide their selection of food and other goods to customers through Instacart's mobile app or website. After a customer places an order, an independent personal shopper employed by Instacart will pick the order and either prepare it for pickup or deliver it to the customer's chosen location. Instacart's revenue model consists of transaction revenue in the form of retailer and customer fees, as well as advertising revenue from brand advertising on Instacart platforms.
<h3>Maplebear's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Maplebear showcased positive performance, achieving a revenue growth rate of 6.08% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Maplebear's net margin is impressive, surpassing industry averages. With a net margin of 16.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Maplebear's ROA stands out, surpassing industry averages. With an impressive ROA of 2.91%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Maplebear's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CART

What 10 Analyst Ratings Have To Say About Maplebear

TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TScan Therapeutics and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $15.00 and a low estimate of $9.00. Surpassing the previous average price target of $7.00, the current average has increased by 53.57%.
<img src="https://www.benzinga.com/files/images/story/2024/1713895276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of TScan Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$9.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TScan Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TScan Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for TScan Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into TScan Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TScan Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into TScan Therapeutics's Background</h2>
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
<h3>Breaking Down TScan Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: TScan Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 132.99%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: TScan Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -271.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): TScan Therapeutics's ROE excels beyond industry benchmarks, reaching -12.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -6.96%, the company showcases effective utilization of assets.
Debt Management: TScan Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.61. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TCRX

Unveiling 4 Analyst Insights On TScan Therapeutics

4 analysts have expressed a variety of opinions on Everi Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Everi Hldgs and provided 12-month price targets. The average target is $12.25, accompanied by a high estimate of $13.00 and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 18.33%. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895256_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Everi Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Bain</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Everi Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Everi Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Everi Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Everi Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVRI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Everi Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Everi Hldgs's Background</h2>
Everi Holdings Inc provides entertainment and technology solutions for the casino, interactive, and gaming industry. It operates in two segments namely Games and Financial Technology Solutions (FinTech). Enveri Games provides gaming operators with gaming technology products and services which include gaming machines, slot machines, leased gaming equipment, and other products and services. Enveri FinTech provides gaming operators with financial technology products and services which include services and equipment that facilitate casino patron's to access cash at gaming facilities through automated teller machines, point of sale debit card purchases and others.
<h3>Financial Milestones: Everi Hldgs's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Everi Hldgs's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -6.49%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Everi Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Everi Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 0.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Everi Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Everi Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 4.34, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVRI

Analyst Scoreboard: 4 Ratings For Everi Hldgs

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $96.5, a high estimate of $109.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 6.63% increase from the previous average price target of $90.50.
<img src="https://www.benzinga.com/files/images/story/2024/1713895242_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Pinnacle Finl Partners by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Casey Haire</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pinnacle Finl Partners. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pinnacle Finl Partners's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pinnacle Finl Partners's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pinnacle Finl Partners analyst ratings.</a>
<h2>Get to Know Pinnacle Finl Partners Better</h2>
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. Pinnacle operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
<h3>Unraveling the Financial Story of Pinnacle Finl Partners</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Pinnacle Finl Partners's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -33.55%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Pinnacle Finl Partners's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 39.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pinnacle Finl Partners's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pinnacle Finl Partners's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pinnacle Finl Partners's debt-to-equity ratio is below the industry average at 0.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNFP

Cracking The Code: Understanding Analyst Reviews For Pinnacle Finl Partners

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.8, with a high estimate of $83.00 and a low estimate of $72.00. Observing a 9.19% increase, the current average has risen from the previous average price target of $71.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895233_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of ANI Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ANI Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ANI Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into ANI Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About ANI Pharmaceuticals</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 39.71%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 0.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ANI Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 0.08%. This signifies efficient management of assets and strong financial health.
Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts

Applied Digital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NYSE">APLD</a>) short percent of float has risen 9.17% since its last report. The company recently reported that it has 21.13 million shares sold short, which is 21.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied Digital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895227_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied Digital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Applied Digital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied Digital's peer group average for short interest as a percentage of float is 5.66%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

APLD

How Is The Market Feeling About Applied Digital?

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has fallen 21.4% since its last report. The company recently reported that it has 6.25 million shares sold short, which is 5.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTRA

Looking Into Natera's Recent Short Interest

New York Community's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) short percent of float has risen 12.26% since its last report. The company recently reported that it has 75.57 million shares sold short, which is 10.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>New York Community Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713895216_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New York Community has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing New York Community's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, New York Community's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NYCB

Peering Into New York Community's Recent Short Interest

In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.2, a high estimate of $57.00, and a low estimate of $35.00. This current average reflects an increase of 52.32% from the previous average price target of $30.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1713895212_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Beam Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$35.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Beam Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Beam Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Beam Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Beam Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Beam Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Beam Therapeutics</h2>
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
<h3>Key Indicators: Beam Therapeutics's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Beam Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1478.04%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Beam Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 45.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Beam Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Beam Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.38% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.